Dulaglutide vs Semaglutide
Dulaglutide (GLP-1 receptor agonist) and Semaglutide (GLP-1 receptor agonist) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | Dulaglutide | Semaglutide |
|---|---|---|
| Compound class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Research category | GLP-1 Family | GLP-1 Family |
| Length (amino acids) | Not documented | 31 amino acids |
| Molecular weight | ~59700 g/mol | 4113.6 g/mol |
| Half-life | ~5 days | ~7 days |
| Origin | Developed by Eli Lilly as a GLP-1 receptor agonist in which a modified GLP-1 analog is fused to a human IgG4 Fc fragment. It received first FDA approval in 2014. | Developed by Novo Nordisk as a long-acting analog of the human incretin hormone GLP-1, building on the earlier once-daily liraglutide. It received first regulatory approvals in 2017 (injectable) and 2019 (oral). |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How Dulaglutide works
Dulaglutide is a fusion protein consisting of two modified human GLP-1 analog peptides covalently linked to a human immunoglobulin G4 (IgG4) Fc fragment. The GLP-1 portions activate the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Fc fusion increases molecular size and resistance to degradation, giving a long half-life that supports once-weekly dosing.
How Semaglutide works
Semaglutide is a structurally modified analog of native glucagon-like peptide-1 (GLP-1) that binds and activates the GLP-1 receptor. Receptor activation enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and acts on central appetite-regulating pathways to reduce food intake. Its backbone modifications and a C18 fatty-acid (diacid) side chain promote albumin binding and resistance to DPP-4 degradation, giving it a prolonged duration of action.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
Described in identical terms for both
Dulaglutide
Semaglutide
What sets each apart
Dulaglutide
Dulaglutide differs structurally from most GLP-1 agonists by being an Fc-fusion protein, achieving long duration through antibody-fragment fusion rather than fatty-acid acylation.
Semaglutide
Unlike dual or triple agonists, semaglutide is a selective GLP-1 receptor agonist. Its once-weekly dosing and availability in an oral form distinguish it from the older once-daily liraglutide.
Frequently asked questions
How does dulaglutide differ from semaglutide?
Both are once-weekly GLP-1 agonists, but dulaglutide is an Fc-fusion protein while semaglutide is an acylated peptide, and in the reported comparisons semaglutide is generally associated with larger weight and glycemic effects. Dulaglutide is the earlier-generation weekly reference agonist. The structural difference is the key mechanistic contrast.
What is dulaglutide and how is its structure unusual for a GLP-1 agonist?
Dulaglutide is a GLP-1 receptor agonist built as a fusion protein: two GLP-1 analogue peptides linked to a modified human IgG4 Fc fragment. The Fc fusion (rather than fatty-acid acylation) is what extends its half-life and enables once-weekly dosing. This makes it structurally larger and distinct from the acylated small-peptide GLP-1 agonists.
What is dulaglutide's half-life and what does it mean for study design?
Dulaglutide has a reported half-life of about 5 days (~4.7 days), supporting once-weekly administration in the literature. Steady state is generally reached after roughly 2-4 weeks of weekly dosing. Its Fc-fusion size also means it behaves more like an antibody-fusion biologic than a small peptide in handling terms.
What is semaglutide and what receptor does it target?
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist derived from the native GLP-1 peptide with amino-acid substitutions and a C18 fatty-diacid chain that binds albumin to extend its half-life. In research it is studied as a reference GLP-1 agonist in models of glucose regulation, appetite/food intake, and body-weight change. It is the mono-agonist against which many newer multi-receptor compounds are benchmarked.
What does semaglutide's long half-life mean for research design?
Semaglutide has a reported plasma half-life of roughly 7 days (about 155-184 hours), which is why once-weekly administration is used in the published literature. Steady-state concentrations are typically reached after about 4-5 weeks at a given dose level, so study designs generally include a multi-week dose-escalation before any maintenance-phase readout. This slow kinetics also means washout after discontinuation spans several weeks.
How is semaglutide dose-escalated in the research literature?
Published protocols use a stepwise weekly escalation, commonly 0.25 mg, then 0.5, 1.0, 1.7, and up to 2.4 mg once weekly, with each step typically held about 4 weeks. Escalation is used in the literature to reduce gastrointestinal tolerability issues rather than starting at the top dose. These are reference figures for research context only, not dosing guidance for humans.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.